Sustained JNK1 Activation is Associated with Altered Histone H3 Methylations in Human Liver Cancer

Overview

Journal J Hepatol

Publisher Elsevier

Specialty Gastroenterology

Date 2008 Dec 2

PMID 19041150

Citations 59

Authors

Qingshan Chang

Yadong Zhang

Kevin J Beezhold

Deepak Bhatia

Hongwen Zhao

Jianguo Chen

Vince Castranova

Xianglin Shi

Fei Chen

Affiliations

Soon will be listed here.

Abstract

Background/aims: Aberrant c-Jun N-terminal kinase (JNK) activation has been linked to hepatocellular carcinoma (HCC) in mouse models. It remains unclear whether JNK activation plays an important role in human HCC and, if so, how JNK signaling contributes to the initiation or progression of HCC.

Methods: The JNK activation, global gene expression, and the status of histone H3 methylations were measured in 31 primary human hepatocellular carcinoma (HCC) samples paired with the adjacent non-cancerous (ANC) tissues.

Results: Enhanced JNK1 activation was noted in 17 out of 31 HCC samples (55%) relative to the corresponding ANC tissues, whereas JNK2 activation was roughly equal between HCC and ANC tissues. This enhancement in JNK1 activation is associated with an increased tumor size and a lack of encapsulation of the tumors. In addition, an association of JNK1 activation with the histone H3 lysines 4 and 9 tri-methylation was observed in the HCC tissues, which leads to an elevated expression of genes regulating cell growth and a decreased expression of the genes for cell differentiation and the p450 family members in HCC.

Conclusions: These results, thus, suggest that JNK1 plays important roles in the development of human HCC partially through the epigenetic mechanisms.

Citing Articles

Components of the JNK-MAPK pathway play distinct roles in hepatocellular carcinoma.

Yu J, Li X, Cao J, Zhu T, Liang S, Du L J Cancer Res Clin Oncol. 2023; 149(19):17495-17509.

PMID: 37902853 DOI: 10.1007/s00432-023-05473-9.

DNMT1/PKR double knockdowned HepG2 (HepG2-DP) cells have high hepatic function and differentiation ability.

Tanaka-Yachi R, Aizawa K, Shimizu K, Akutsu H, Nakamura K Sci Rep. 2022; 12(1):21173.

PMID: 36476676 PMC: 9729623. DOI: 10.1038/s41598-022-25777-z.

Drug Discovery of DKK1 Inhibitors.

Jiang H, Zhang Z, Yu Y, Chu H, Yu S, Yao S Front Pharmacol. 2022; 13:847387.

PMID: 35355709 PMC: 8959454. DOI: 10.3389/fphar.2022.847387.

Roles of Therapeutic Bioactive Compounds in Hepatocellular Carcinoma.

Jain D, Murti Y, Khan W, Hossain R, Hossain M, Agrawal K Oxid Med Cell Longev. 2021; 2021:9068850.

PMID: 34754365 PMC: 8572616. DOI: 10.1155/2021/9068850.

Probing Synergistic Targets by Natural Compounds for Hepatocellular Carcinoma.

Gao J, Yin Z, Wu Z, Sheng Z, Ma C, Chen R Front Cell Dev Biol. 2021; 9:715762.

PMID: 34395446 PMC: 8355820. DOI: 10.3389/fcell.2021.715762.

References

Chen F, Lu Y, Zhang Z, Vallyathan V, Ding M, Castranova V . Opposite effect of NF-kappa B and c-Jun N-terminal kinase on p53-independent GADD45 induction by arsenite. J Biol Chem. 2001; 276(14):11414-9. DOI: 10.1074/jbc.M011682200. View

Keshet I, Schlesinger Y, Farkash S, Rand E, Hecht M, Segal E . Evidence for an instructive mechanism of de novo methylation in cancer cells. Nat Genet. 2006; 38(2):149-53. DOI: 10.1038/ng1719. View

Lu C, Bonome T, Li Y, Kamat A, Han L, Schmandt R . Gene alterations identified by expression profiling in tumor-associated endothelial cells from invasive ovarian carcinoma. Cancer Res. 2007; 67(4):1757-68. DOI: 10.1158/0008-5472.CAN-06-3700. View

Matsukawa Y, Semba S, Kato H, Ito A, Yanagihara K, Yokozaki H . Expression of the enhancer of zeste homolog 2 is correlated with poor prognosis in human gastric cancer. Cancer Sci. 2006; 97(6):484-91. PMC: 11159019. DOI: 10.1111/j.1349-7006.2006.00203.x. View

Reik W . Stability and flexibility of epigenetic gene regulation in mammalian development. Nature. 2007; 447(7143):425-32. DOI: 10.1038/nature05918. View

Kel A, Konovalova T, Waleev T, Cheremushkin E, Kel-Margoulis O, Wingender E . Composite Module Analyst: a fitness-based tool for identification of transcription factor binding site combinations. Bioinformatics. 2006; 22(10):1190-7. DOI: 10.1093/bioinformatics/btl041. View

Schlesinger Y, Straussman R, Keshet I, Farkash S, Hecht M, Zimmerman J . Polycomb-mediated methylation on Lys27 of histone H3 pre-marks genes for de novo methylation in cancer. Nat Genet. 2007; 39(2):232-6. DOI: 10.1038/ng1950. View

Xie Y, Liu J, Benbrahim-Tallaa L, Ward J, Logsdon D, Diwan B . Aberrant DNA methylation and gene expression in livers of newborn mice transplacentally exposed to a hepatocarcinogenic dose of inorganic arsenic. Toxicology. 2007; 236(1-2):7-15. PMC: 2465467. DOI: 10.1016/j.tox.2007.03.021. View

Chen Y, Lin M, Yao H, Wang H, Zhang A, Yu J . Lentivirus-mediated RNA interference targeting enhancer of zeste homolog 2 inhibits hepatocellular carcinoma growth through down-regulation of stathmin. Hepatology. 2007; 46(1):200-8. DOI: 10.1002/hep.21668. View

10.

Miotto B, Sagnier T, Berenger H, Bohmann D, Pradel J, Graba Y . Chameau HAT and DRpd3 HDAC function as antagonistic cofactors of JNK/AP-1-dependent transcription during Drosophila metamorphosis. Genes Dev. 2006; 20(1):101-12. PMC: 1356104. DOI: 10.1101/gad.359506. View

11.

Chen F, Castranova V, Li Z, Karin M, Shi X . Inhibitor of nuclear factor kappaB kinase deficiency enhances oxidative stress and prolongs c-Jun NH2-terminal kinase activation induced by arsenic. Cancer Res. 2003; 63(22):7689-93. View

12.

Llovet J, Di Bisceglie A, Bruix J, Kramer B, Lencioni R, Zhu A . Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst. 2008; 100(10):698-711. DOI: 10.1093/jnci/djn134. View

13.

Chen Y, Lin M, Wang H, Chan C, Jiang L, Ngai S . Proteomic analysis of EZH2 downstream target proteins in hepatocellular carcinoma. Proteomics. 2007; 7(17):3097-104. DOI: 10.1002/pmic.200700019. View

14.

Tsunedomi R, Iizuka N, Hamamoto Y, Uchimura S, Miyamoto T, Tamesa T . Patterns of expression of cytochrome P450 genes in progression of hepatitis C virus-associated hepatocellular carcinoma. Int J Oncol. 2005; 27(3):661-7. View

15.

Weston C, Davis R . The JNK signal transduction pathway. Curr Opin Cell Biol. 2007; 19(2):142-9. DOI: 10.1016/j.ceb.2007.02.001. View

16.

Kyriakis J, Avruch J . pp54 microtubule-associated protein 2 kinase. A novel serine/threonine protein kinase regulated by phosphorylation and stimulated by poly-L-lysine. J Biol Chem. 1990; 265(28):17355-63. View

17.

Wong C, Lee J, Ching Y, Jin D, Ng I . Genetic and epigenetic alterations of DLC-1 gene in hepatocellular carcinoma. Cancer Res. 2003; 63(22):7646-51. View

18.

Kleer C, Cao Q, Varambally S, Shen R, Ota I, Tomlins S . EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci U S A. 2003; 100(20):11606-11. PMC: 208805. DOI: 10.1073/pnas.1933744100. View

19.

Hess P, Pihan G, Sawyers C, Flavell R, Davis R . Survival signaling mediated by c-Jun NH(2)-terminal kinase in transformed B lymphoblasts. Nat Genet. 2002; 32(1):201-5. DOI: 10.1038/ng946. View

20.

Latulippe E, Satagopan J, Smith A, Scher H, Scardino P, Reuter V . Comprehensive gene expression analysis of prostate cancer reveals distinct transcriptional programs associated with metastatic disease. Cancer Res. 2002; 62(15):4499-506. View